Introduction: Status epilepticus (SE) is a lifethreatening neurological emergency. SE lasting longer than 120 min and not responding to first-line and second-line antiepileptic drugs is defined as 'refractory' (RCSE) and requires intensive care unit treatment. There is currently neither evidence nor consensus to guide either the optimal choice of therapy or treatment goals for RCSE, which is generally treated with coma induction using conventional anaesthetics (high dose midazolam, thiopental and/or propofol). Increasing evidence indicates that ketamine (KE), a strong N-methyl-D-aspartate glutamate receptor antagonist, may be effective in treating RCSE. We hypothesised that intravenous KE is more efficacious and safer than conventional anaesthetics in treating RCSE. Methods and analysis: A multicentre, randomised, controlled, open-label, non-profit, sequentially designed study will be conducted to assess the efficacy of KE compared with conventional anaesthetics in the treatment of RCSE in children. 10 Italian centres/ hospitals are involved in enrolling 57 patients aged 1 month to 18 years with RCSE. Primary outcome is the resolution of SE up to 24 hours after withdrawal of therapy and is updated for each patient treated according to the sequential method. Ethics and dissemination: The study received ethical approval from the Tuscan Paediatric Ethics Committee (12/2015). The results of this study will be published in peer-reviewed journals and presented at international conferences.

Rosati, A., Ilvento, L., L'Erario, M., Masi, S. D., Biggeri, A., Fabbro, G., Bianchi, R., Stoppa, F., Fusco, L., Pulitanò, S. M. M., Battaglia, D., Pettenazzo, A., Sartori, S., Biban, P., Fontana, E., Cesaroni, E., Mora, D., Costa, P., Meleleo, R., Vittorini, R., Conio, A., Wolfler, A., Mastrangelo, M., Mondardini, M. C., Franzoni, E., Mcgreevy, K. S., Simone, L. D., Pugi, A., Mirabile, L., Vigevano, F., Guerrini, R., Efficacy of ketamine in refractory convulsive status epilepticus in children: A protocol for a sequential design, multicentre, randomised, controlled, open-label, non-profit trial (KETASER01), <<BMJ OPEN>>, 2016; 6 (6): N/A-N/A. [doi:10.1136/bmjopen-2016-011565] [http://hdl.handle.net/10807/95284]

Efficacy of ketamine in refractory convulsive status epilepticus in children: A protocol for a sequential design, multicentre, randomised, controlled, open-label, non-profit trial (KETASER01)

Bianchi, Roberto;Pulitanò, Silvia Maria Modesta;Battaglia, Domenica;
2016

Abstract

Introduction: Status epilepticus (SE) is a lifethreatening neurological emergency. SE lasting longer than 120 min and not responding to first-line and second-line antiepileptic drugs is defined as 'refractory' (RCSE) and requires intensive care unit treatment. There is currently neither evidence nor consensus to guide either the optimal choice of therapy or treatment goals for RCSE, which is generally treated with coma induction using conventional anaesthetics (high dose midazolam, thiopental and/or propofol). Increasing evidence indicates that ketamine (KE), a strong N-methyl-D-aspartate glutamate receptor antagonist, may be effective in treating RCSE. We hypothesised that intravenous KE is more efficacious and safer than conventional anaesthetics in treating RCSE. Methods and analysis: A multicentre, randomised, controlled, open-label, non-profit, sequentially designed study will be conducted to assess the efficacy of KE compared with conventional anaesthetics in the treatment of RCSE in children. 10 Italian centres/ hospitals are involved in enrolling 57 patients aged 1 month to 18 years with RCSE. Primary outcome is the resolution of SE up to 24 hours after withdrawal of therapy and is updated for each patient treated according to the sequential method. Ethics and dissemination: The study received ethical approval from the Tuscan Paediatric Ethics Committee (12/2015). The results of this study will be published in peer-reviewed journals and presented at international conferences.
Inglese
Rosati, A., Ilvento, L., L'Erario, M., Masi, S. D., Biggeri, A., Fabbro, G., Bianchi, R., Stoppa, F., Fusco, L., Pulitanò, S. M. M., Battaglia, D., Pettenazzo, A., Sartori, S., Biban, P., Fontana, E., Cesaroni, E., Mora, D., Costa, P., Meleleo, R., Vittorini, R., Conio, A., Wolfler, A., Mastrangelo, M., Mondardini, M. C., Franzoni, E., Mcgreevy, K. S., Simone, L. D., Pugi, A., Mirabile, L., Vigevano, F., Guerrini, R., Efficacy of ketamine in refractory convulsive status epilepticus in children: A protocol for a sequential design, multicentre, randomised, controlled, open-label, non-profit trial (KETASER01), <<BMJ OPEN>>, 2016; 6 (6): N/A-N/A. [doi:10.1136/bmjopen-2016-011565] [http://hdl.handle.net/10807/95284]
File in questo prodotto:
File Dimensione Formato  
e011565.full.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 1.12 MB
Formato Unknown
1.12 MB Unknown Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/95284
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 29
  • ???jsp.display-item.citation.isi??? 20
social impact